Microba Secures Funding to Drive Growth and Cashflow Break-even
Microba Life Sciences (ASX: MAP) has secured commitments for a AU$5.0 million placement, with support from existing and new investors, including strategic shareholder Sonic Healthcare. The capital raising is designed to fund the company’s growth strategy, support the launch of a new diagnostics product, strengthen working capital, and advance its goal of achieving company-wide cashflow break-even on a run-rate basis by CY2027. The company also intends to launch a share purchase plan of up to AU$1.0 million, providing eligible shareholders with an opportunity to participate in the capital raising.
The company continues to demonstrate strong momentum in its diagnostics business, recording 11 consecutive quarters of core testing sales growth and a 106% increase in core testing sales over the past year. Growth is being supported by increasing adoption from healthcare clinic networks in Australia and the UK, while a new microbiome testing product scheduled for launch in Q3 CY26 is expected to provide an additional growth catalyst. Microba is also progressing partnership discussions for its therapeutics portfolio, including its Phase 2-ready MAP 315 asset, following encouraging developments across the microbiome therapeutics sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Microba Secures Funding to Drive Growth and Cashflow Break-even
Microba Life Sciences (ASX: MAP) has secured commitments for a AU$5.0 million placement, with support from existing and new investors, including strategic shareholder Sonic Healthcare. The capital raising is designed to fund the company’s growth strategy, support the launch of a new diagnostics product, strengthen working capital, and advance its goal of achieving company-wide cashflow break-even on a run-rate basis by CY2027. The company also intends to launch a share purchase plan of up to AU$1.0 million, providing eligible shareholders with an opportunity to participate in the capital raising.
The company continues to demonstrate strong momentum in its diagnostics business, recording 11 consecutive quarters of core testing sales growth and a 106% increase in core testing sales over the past year. Growth is being supported by increasing adoption from healthcare clinic networks in Australia and the UK, while a new microbiome testing product scheduled for launch in Q3 CY26 is expected to provide an additional growth catalyst. Microba is also progressing partnership discussions for its therapeutics portfolio, including its Phase 2-ready MAP 315 asset, following encouraging developments across the microbiome therapeutics sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au